On a roll, Ver­tex grabs FDA OK for CF dou­ble shot Symdeko — prices at $292,000

Close on the heels of its im­pres­sive da­ta on new triple com­bos for cys­tic fi­bro­sis, Ver­tex re­port­ed out to­day that the FDA has ap­proved its dou­ble us­ing teza­caftor/iva­caftor.

In a dri­ve to con­tin­u­al­ly ex­pand on its rev­enue, Ver­tex an­nounced that it will price the com­bo at $292,000 a year, putting it in line for steadi­ly swelling rev­enue num­bers for the year ahead.

The com­bo will be mar­ket­ed as Symdeko to any­one 12 and over with at least one mu­ta­tion that is re­spon­sive to the dou­ble.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER